Investment opportunities

Oxford University Innovation constantly seeks investors for its new technology companies and organises its investor network through the Oxford Angels Network (OAN).

Invest in new technology companies

If you are looking to invest in new technology companies, you can find all our technology investment opportunities below:

No investor has acquired any first rights to invest in new Oxford University spinout companies, and Oxford University Innovation seeks investments into its spinouts from all investors.

Oxford’s spinout scene is vibrant, with between 15 to 20 university spinout opportunities being actively managed at any time in the pipeline.

Technology licensing to spinouts

Oxford University Innovation offers a standardised approach for licensing IP to new spinout companies on their formation, designed to support the thriving spinout ecosystem with simple licence terms and streamlined process. It ensures that financial returns to the inventors and University align directly with the returns to investors and commercial success of the companies formed, while giving maximum opportunity for the companies to thrive.

This approach is intended to boost both the volume and value of translated science from Oxford.

The licence for new spinouts has a structure that defers the majority of payments until an exit event or products reach the market, and includes:

  • a fixed completion fee plus repayment of past patent costs
  • a cash payment upon sale or exit of the venture
  • no milestone or minimum sum payments
  • no royalties on net sales are payable until a set threshold of sales has been reached

This licence is available only to spinouts intending to raise investment and only with standard legal terms, intended to speed up completion of the first round of investment and simplify processes post-completion. The document template can be downloaded here: OUI Spinout Express Licence (pdf, 724KB).

Oxford University Innovation’s previous practice was to structure a licence bespoke for each spinout company. These licences were mostly royalty based with milestones and minimum periodic payments. Should the spinout opt not to use the above standardised approach, Oxford University Innovation remains able to work with them to construct bespoke licence terms.

Please read the disclaimer regarding investment opportunities publicised, and contact us if you need further information.

MeVitae

7th February 2017
Business, finance and management | Software and computer services

At the moment, recruiters don’t have time to make careful decisions, so they often hire the wrong people.  That costs money – UK businesses waste about £1 billion per year due to bad hiring.  MeVitae has built an intelligen...

Read more

Inkpath

7th February 2017
Education | Software and computer services

Company Background Inkpath is the first comprehensive, data-driven software platform to help its users plan and track their career development in a smart format, with user mobility at its core. Our smartphone app and database, wh...

Read more

Dynamic Consent

20th December 2016
e-Health | Pharmaceuticals, therapeutics and drug discovery | Software and computer services

Recruitment and retention of participants for biobanks, personalised medicine and clinical trials are critical as these activities support the provision of critical resources, generation of enabling data and ensure new interventio...

Read more

Noble.ai

12th December 2016
Aerospace, defence and security | Business, finance and management | Economics | Energy | Genetics, genomic and proteomics | Pharmaceuticals, therapeutics and drug discovery | Research tools and materials | Software and computer services

Noble.ai is harnessing a ground-breaking approach to Big Data Analytics, which enables a diverse user-base to make unprecedented discoveries from large datasets. The proprietary methodology applies a fundamentally superior approac...

Read more

Oxford Antibiotics

22nd March 2016
Pharmaceuticals, therapeutics and drug discovery

Opportunity Team - Dr. Alexander Pretsch (CEO designate), Prof. Mark Moloney (Academic Founder) Vision - To bring a new first-in-class drug into the antibiotic market that provides a clear commercial advantage by following t...

Read more

Search

Ready to get in touch?

Contact Us
Search
© Oxford University Innovation